Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Ibrutinib in Advanced Melanoma
NCT03021460Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jan 2017
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrutinib in melanoma, sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose and Objective Response Rate up to 5 years. Started Jan 2017; status: completed.
02
Drugs
ibrutinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03021460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03021460.